Scientists at Jerusalem’s Hadassah hospital and Bar-Ilan University have developed HBI0101- a CAR-T therapy for multiple myeloma and amyloidosis, benefiting over 90% of patients in trials. Los Angeles-based Immix BioPharma will commercialize HBI0101. https://www.timesofisrael.com/after-demonstrating-57-remission-rate-israeli-immunotherapy-licensed-by-us-firm/ https://haematologica.org/article/view/haematol.2022.281628

Social worker Tali used to support staff at Hadassah’s Jerusalem Medical Center. Now her colleagues administer Hadassah’s CAR-T therapy (in Phase 1 trials see here) to hopefully cure Tali’s multiple myeloma. Hadassah hopes to develop cellular therapy for any type … Continue reading →

Scientists at Israel’s Bar-Ilan University and Hadassah-University Medical Center, have developed a treatment for multiple myeloma. The patient’s T-cells are combined with a chimeric antigen receptor (CAR) molecule. In Phase 1 human trials at Hadassah. https://www.jpost.com/health-science/groundbreaking-made-in-israel-treatment-may-offer-cure-for-blood-cancer-664422